Alzheimer’s Drugs Market, by Drug (Donepezil, Rivastigmine, Galantamine and Memantine), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region - Global Forecast to 2025

  • Published On : Mar 2018 |
  • Pages : 180 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Alzheimer’s Drugs Market - Young Prospect for Aging Patient

Alzheimer’s is a form of dementia, which affect behavior, thinking, and memory of patient. The progression of disease is slow and it degrades neurons associated with learning part of cerebrum. It is most common and largest form of dementia (more than 60%), which is observed in people of age 65 and above. Accumulation of protein called as beta amyloid in spaces between nerve cells due to genetic mutation is major cause of Alzheimer. Although Alzheimer’s disease is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop treatment centered on the role of beta-amyloid in Alzheimer’s disease.

The global Alzheimer’s drugs market was valued at US$ 7 billion in 2016 and is expected to witness a CAGR of 9.5% over the forecast period (2017 - 2025).

Figure 1. Global Alzheimer’s Drugs Market (US$ Bn), by Region, 2016

alzheimer's drugs market

Source: Coherent Market Insights

Increasing prevalence of Alzheimer’s disease to drive growth of the Alzheimer’s drugs market worldwide

Increasing prevalence and incidence of Alzheimer’s disease worldwide is expected to drive the growth of Alzheimer’s disease therapeutics market. According to World Alzheimer Report in 2016, an estimated 46.5 million people were suffering from Alzheimer’s disease and the number is projected to reach 50 million by 2017, every three second there is new patient of Alzheimer’s disease worldwide.

Increasing age and aging global population are major risk factors for Alzheimer’s, which increase the disease incidence and provide growth opportunity for Alzheimer’s treatment market. For instance, according to World Population Prospects (WPP) published by United Nations in 2017, an estimated 962 million people are of age 60 or above, which accounted for 13 per cent of the global population. The number is projected to reach 1.4 billion by 2030, growing with annual rate of 3 percent. Europe currently has highest geriatric population (25% of population), Asia Pacific had geriatric population of 547 million people and it is projected to reach 900 million by 2025, therefore these regions have potential opportunity for growth of the market. India has more than 1 million cases of Alzheimer’s disease annually. North America holds dominant position in the Alzheimer’s disease therapeutics market with estimated 5.5. Mn patients in 2017. The robust healthcare infrastructure in the region, and the region being an early adopter of novel technologies, positions it as a major market for Alzheimer’s disease.

Large number of undiagnosed patient’s and revised diagnostic guidelines to propel growth for Alzheimer’s drugs market

People suffering from early stage of Alzheimer’s disease with some dementia do not have appropriate access to the healthcare infrastructure to diagnose and treat the disease. For instance according to World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle income economies, therefore, this is expected to propel growth of Alzheimer’s drugs market. As of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis develop treatment for Alzheimer’s disease. Currently, there is no curative therapy available for Alzheimer’s disease. However, drugs for Alzheimer’s therapy are in pipeline, which are expected to launch in near future, which in turn is propelling growth of Alzheimer’s disease therapeutics market.

Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.

The Alzheimer’s disease is one of the most prevalent neurodegenerative disease, which is associated proportionately with increased life expectancy worldwide. Patient suffers and encounters various behavioral change with dementia, as a primary symptoms, which gets worse as disease progress. It majorly affects people of age group 65 and above. Currently, there is no therapeutic cure available for Alzheimer’s disease, however, available drugs can lower symptoms or severity of the disease. Although many companies have invested in the development of new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in condition of patient and many of those investigational candidates failed to provide significant improvement in patients condition during phase three clinical trials.

Market Dynamics

Major factor fueling growth of the Alzheimer’s drugs market is large number of drugs in pipeline, which are expected to enter into market by 2022. According to the study published by Translational Research and Clinical Intervention in September 2017, there are 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products has novel approach such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, serotonin 5-HT6 receptor antagonist. Along with this there is an increase amount of collaboration amongst companies for developing drugs in joint effort, for instance in November 2017, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to  prevent or delay symptoms of Alzheimer's disease. In 2016, AstraZeneca and Eli Lilly and Company entered into worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials, as a potential disease-modifying treatment for Alzheimer’s disease. These collaborations are expected to accelerate the development process and bring efficiency in entire arena of operations. However, failing of investigational candidate in late stage is expected to be a huge setback in the current Alzheimer’s drugs market, for instance in February 2017, an external data monitoring committee warned that Merck & Co. terminated study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study.

Key features of the study:

  • This report provides in-depth analysis of Alzheimer’s drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global Alzheimer’s drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global Alzheimer’s drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Alzheimer’s drugs market

Detailed Segmentation:

  • Global Alzheimer’s Drugs Market, By Drugs:
    • Donepezil
    • Rivastigmine
    • Galantamine
    • Memantine
  • Global Alzheimer’s Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • Global Alzheimer’s Drugs Market, By Geography:
    • North America
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments
      • Key Strategies
    • Janssen Pharmaceuticals
    • Novartis International AG
    • Eisai Co. Ltd
    • Lundbeck A/S
    • Teva Pharmaceuticals Industries Ltd
    • Daichi Sankyo Company Limited

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drugs
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Highlights
    • Pipeline Analysis
    • Regulatory Guidelines
    • Epidemiology
  4. Global Alzheimer’s Drugs Market, By Drugs, 2015 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016 – 2025
      • Segment Trends
    • Donepezil
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
    • Rivastigmine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
    • Galantamine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
    • Memantine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
  5. Global Alzheimer’s Drugs Market, By Distribution Channel, 2015 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016 – 2025
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
    • e-Commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
  6. Global Alzheimer’s Drugs Market, By Region, 2015 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2016 – 2025
    • North America
      • Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profiles
      • Pfizer Inc.*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Developments
        • Strategies
      • Janssen Pharmaceutical.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Developments
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Developments
        • Strategies
      • Teva Pharmaceuticals ltd.
        •  Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Developments
        • Strategies
      • Eisai Co Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Developments
        • Strategies
      • Lundbeck A/S.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Developments
        • Strategies
      • Daichi Sankyo Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Developments
        • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 48 market data tables and 28 figures on "Alzheimer’s Drugs Market - Global forecast to 2025”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.